Hendriks, Pim http://orcid.org/0000-0002-4992-9967
Rietbergen, Daphne D. D.
van Erkel, Arian R.
Coenraad, Minneke J.
Arntz, Mark J.
Bennink, Roel J.
Braat, Andries E.
Crobach, A. Stijn L. P.
van Delden, Otto M.
van der Hulle, Tom
Klümpen, Heinz-Josef
van der Meer, Rutger W.
Nijsen, J. Frank W.
van Rijswijk, Carla S. P.
Roosen, Joey
Ruijter, Bastian N.
Smit, Frits
Stam, Mette K.
Takkenberg, R. Bart
Tushuizen, Maarten E.
van Velden, Floris H. P.
de Geus-Oei, Lioe-Fee
Burgmans, Mark C.
,
Funding for this research was provided by:
Health~Holland (40-41200-98-9286)
Article History
Received: 30 September 2021
Accepted: 23 April 2022
First Online: 26 May 2022
Declarations
:
: M.C. Burgmans has received an educational grant from Boston Scientific. None are related to the current project. J.F.W. Nijsen is co-founder and part time scientific director of Quirem Medical which has been acquired by Terumo Europe NV in July 2020. Nijsen is entitled to certain milestone payments from Terumo which are related to Quirem’s financial, operational and regulatory performance in the future. Furthermore, Nijsen is inventor on the patents related to radioactive microspheres that are assigned to University Medical Center Utrecht Holding BV, Quirem Medical or BASF Corp. The activities of J.F.W. Nijsen within Quirem Medical are approved and supported by the Board of Directors of the Radboudumc. All other authors declare that they have no conflict of interest.
: For this type of study, consent for publication is not required.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Approval of this study was provided by the Committee of Medical Ethics of the Leiden University Medical Center (NL61926.058.17).
: Informed consent was obtained from all individual participants included in the study.